Percent with a Fragility Fracture Filling Prescription for an Osteoporosis Drug within Six Months
  • Print
  • PDF
  • Embed

    Copy the following code and paste it into your website in order to display the current report.

  • Download to Excel

Customize Report

    • YEAR:

    Choose Locations

    [clear all] [select all] Selected Locations:

      Choose Indicator(s)

      Select one or more indicators
      • TOPIC:
      • INDICATOR:
      • YEAR:

      [clear all] Selected Indicators:


    (Click a region name
    below to view its profile)
    Percent with a Fragility Fracture Filling Prescription for an Osteoporosis Drug within Six Months
    (Year: 2006-2010; Region Levels: State)
    Alaska na
    District of Columbia na
    Idaho 9.9%
    Maine 10.7%
    New Jersey 10.9%
    Vermont 11.7%
    Virginia 11.9%
    Connecticut 12.0%
    New Hampshire 12.1%
    Minnesota 12.3%
    Rhode Island 12.7%
    Kentucky 12.7%
    West Virginia 12.8%
    Utah 13.0%
    Massachusetts 13.2%
    Michigan 13.3%
    Delaware 13.3%
    Maryland 13.3%
    Nebraska 13.4%
    South Dakota 13.5%
    Illinois 13.6%
    Wisconsin 13.6%
    Pennsylvania 13.6%
    Arkansas 13.8%
    Georgia 13.8%
    North Carolina 13.8%
    Wyoming 13.8%
    Mississippi 13.8%
    Missouri 14.0%
    Washington 14.1%
    Arizona 14.2%
    Ohio 14.4%
    Florida 14.4%
    Iowa 14.6%
    North Dakota 14.6%
    Tennessee 14.9%
    New York 15.0%
    South Carolina 15.1%
    Oregon 15.2%
    Texas 15.3%
    Louisiana 15.4%
    Alabama 15.4%
    New Mexico 15.8%
    Kansas 15.8%
    Oklahoma 16.0%
    Nevada 16.4%
    California 16.6%
    Indiana 16.9%
    Colorado 17.3%
    Montana 17.3%
    Hawaii 28.0%
    National Average 14.3%
    90th Percentile 16.6%
    50th Percentile 13.8%
    10th Percentile 11.9%
        • Patients were included in the fragility fracture cohort if they (1) experienced a fracture of the hip, distal forearm or humerus between 5/1/2006 and 12/31/2009, (2) were continuously enrolled in fee-for-service Medicare Parts A and B for at least 36 months preceding the index fracture and at least 12 months following the fracture, (3) were alive and continuously enrolled in and used (one or more fill record) a stand-alone Medicare Part D plan for at least 6 months following the fracture, (4) did not have an identically-defined fragility fracture in the 36 months preceding the index fracture, (5) were predominantly community dwelling (not hospitalized for more than 90 days and had no prescriptions filled by a long-term care pharmacy type) in the first 6 months following index fracture, (6) had no cancer diagnosis (other than non-melanoma skin cancer), hospice enrollment, or managed Medicare enrollment at any time in claims records analyzed.

        • All medication use measures were based on Part D event fill records for the time frame specific to each cohort’s observation. The Lexi-Data Basic database (Lexicomp) was used to obtain the drug name, dose, brand or generic status, and active ingredient according to the National Drug Code (NDC).


    © 2018 The Trustees of Dartmouth College | 35 Centerra Parkway, Lebanon, NH 03766 | (603) 653-0800

    The Dartmouth Atlas of Health Care is based at The Dartmouth Institute for Health Policy and Clinical Practice and is supported by a coalition of funders led by the Robert Wood Johnson Foundation, including the WellPoint Foundation, the United Health Foundation, the California HealthCare Foundation, and the Charles H. Hood Foundation.